Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease

Bibliography

• Jost BC, Grossberg GT. The natural history of Alzheimer's disease: a brain bank study. J Am Geriatr Soc 1995;43:1248-55
   PubMed Web of Science ®Google Scholar
• Smith GE, O'Brien PC, Ivnik RJ, et al. Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology 2001;57:1467-73
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98
   PubMed Web of Science ®Google Scholar
• Schneider LS. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatric Med 2001;17:337-58
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Hyman BT. Alzheimer disease therapeutics. J Neuropathol Exp Neurol 2001;60:923-28
   PubMed Web of Science ®Google Scholar
• Haass C. Take five–BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 2004;23:483-88
   PubMed Web of Science ®Google Scholar
• Hardy J. New insights into the genetics of Alzheimer's disease. Ann Med 1996;28:255-58
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997;275:630-31
   PubMed Web of Science ®Google Scholar
• Lippa CF. Familial Alzheimer's disease: genetic influences on the disease process [review]. Int J Mol Med 1999;4:529-36
   PubMed Web of Science ®Google Scholar
• Lesnė S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-57
   PubMed Web of Science ®Google Scholar
• Siemers ER, Dean RA, Demattos R, et al. New pathways in drug discovery for Alzheimer's disease. Curr Neurol Neurosci Rep 2006;6:372-78
   PubMed Web of Science ®Google Scholar
• Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005;28:126-32
   PubMed Web of Science ®Google Scholar
• Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007;30:317-25
   PubMed Web of Science ®Google Scholar
• Lilly data on file
   Google Scholar
• Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006;66:602-4
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid-beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-38
   PubMed Web of Science ®Google Scholar
• Bateman RJ. Abstract: a-beta turnover in human subjects. Presented at the International Conference on Alzheimer's Disease's (ICAD) 12th Annual Meeting. Chicago, IL, 2008
   Google Scholar
• May PC, Yang Z, Li W, et al. Multi-compartmental pharmaco-dynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice. Neurobiol Aging 2004;25:65
   Google Scholar
• Lanz TA, Karmilowicz MJ, Wood KM, et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 2006;319:924-33
   PubMed Web of Science ®Google Scholar
• Pollack SJ, Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 2005;6:35-47
   PubMedGoogle Scholar
• De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398:518-22
   PubMed Web of Science ®Google Scholar
• Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits A-beta production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82
   PubMed Web of Science ®Google Scholar
• Milner LA, Bigas A. Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Blood 1999;93:2431-48
   PubMed Web of Science ®Google Scholar
• Aisen PS, Gauthier S, Vellas B, et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007;4:473-78
   PubMed Web of Science ®Google Scholar
• Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006;67:1757-63
   PubMed Web of Science ®Google Scholar
• Bellus Health quarterly report, second quarter 2008. Available from: http://www.bellushealth.com/en/pdf/q208_covers_eng.pdf [Last accessed 23 February 2009]
   Google Scholar
• Green RC, Schneider LS, Hendrix SB, et al. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18- month multi-center phase 3 trial. Presented at the International Conference on Alzheimer's Disease's (ICAD) 12th Annual Meeting. Chicago, IL, 2008
   Google Scholar
• Kukar TL, Ladd TB, Bann MA, et al. Substrate-targeting gamma-secretase modulators. Presented at the International Conference on Alzheimer's Disease's (ICAD) 12th Annual Meeting. Chicago, IL, 2008
   Google Scholar
• Holmes C, Boche D, Wilkinson D, et al. Long-term effects of A-beta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-39
   PubMed Web of Science ®Google Scholar
• Selkoe JD. Presented at the International Conference on Alzheimer's Disease's (ICAD) 12th Annual Meeting. Chicago, IL, 2008
   Google Scholar
• Fox NC, Black RS, Gilman S, et al. AN1792(QS-21)-201 Study. Effects of A-beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-72
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS, et al. AN1792(QS-21)-201 Study Team. Clinical effects of A-beta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic A-beta42 (AN1792) in patients with AD. Neurology 2005;64:94-101
   PubMed Web of Science ®Google Scholar
• Schenk DB, Rydel RE, May P, et al. Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. J Med Chem 1995;38:4141-54
   PubMed Web of Science ®Google Scholar
• Meredith J, Thompson L, Toyn J, et al. BMS-708163, a potent and selective γ-secretase inhibitor, decreases CSF Aβ at safe and tolerable doses in animals and humans [abstract HT-01-05]. International Conference on Alzheimer's Disease 26–31 July 2008, Chicago, IL, USA; 2008
   Google Scholar
• Jacobsen S, Comery T, Aschmies S, et al. GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease [abstract P2-302]. Alzheimers Demen 2008;4(Suppl 2):T461
   Google Scholar
• Wan H, Bard J, Martone R, et al. GSI-953, a potent and selective gamma-secretase inhibitor, modulates Aβ peptides in mice and humans: translating the PK/PD biomarker relationships in different biological compartments between rodent and human [abstract P2-101]. Alzheimers Demen 2008;4(Suppl 2):T548
   Google Scholar
• Frick G, Raje S, Wan S, et al. GSI-953, a potent and selective γ-secretase inhibitor – modulation of β amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans [abstract P4-366]. Alzheimers Demen 2008;4(Suppl 2):T781
   Google Scholar
• Imbimbo BP. Alzheimer's disease: γ-secretase inhibitors. Drug Discov Today 2008;5(3):169-75
   Google Scholar
• Hsu HH, Jacobs A, Yu J, et al. Phase 1 safety and pharmacokinetic profile of single doses of CTS21166 (ASP1702) in healthy males [poster P4-454-3501]. International Conference on Alzheimer's Disease 26–31 July 2008, Chicago, IL, USA; 2008
   Google Scholar
• Hey JA, Koelsch G, Bilcer M, et al. Single dose administration of the β-secretase inhibitor CTS21166 (ASP1702) reduces plasma Aβ40 in human subjects [poster P4-422-3497]. International Conference on Alzheimer's Disease 26–31 July 2008, Chicago, IL, USA; 2008
   Google Scholar
• Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aß as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7(9):779-86
   PubMed Web of Science ®Google Scholar